Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes.

Cork, M J; McMichael, A; Teng, J; Valdez, H; Rojo, R; Chan, G; Zhang, F; Myers, D E; DiBonaventura, M

Cork, M J; McMichael, A; Teng, J; Valdez, H; Rojo, R; Chan, G; Zhang, F; Myers, D E; DiBonaventura, M.

Affiliation

Cork MJ; Sheffield Dermatology Research, University of Sheffield, Sheffield, UK.
McMichael A; Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Teng J; Department of Dermatology, Stanford University, Stanford, CA, USA.
Valdez H; Pfizer Inc., New York, NY, USA.
Rojo R; Pfizer Inc., Groton, CT, USA.
Chan G; Pfizer Inc., Groton, CT, USA.
Zhang F; Pfizer Inc., Groton, CT, USA.
Myers DE; Pfizer Inc., Collegeville, PA, USA.
DiBonaventura M; Pfizer Inc., New York, NY, USA.

J Eur Acad Dermatol Venereol ; 36(3): 422-433, 2022 Mar.

Article in En | MEDLINE | ID: mdl-34743361

Subject(s)

Dermatitis, Atopic; Eczema; Pyrimidines/therapeutic use; Sulfonamides/therapeutic use; Adolescent; Child; Dermatitis, Atopic/diagnosis; Dermatitis, Atopic/drug therapy; Double-Blind Method; Eczema/drug therapy; Humans; Patient Reported Outcome Measures; Quality of Life; Severity of Illness Index; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Sulfonamides / Dermatitis, Atopic / Eczema Type of study: Clinical_trials / Diagnostic_studies Aspects: Patient_preference Limits: Adolescent / Child / Humans Language: En Journal: J Eur Acad Dermatol Venereol Year: 2022 Document type: Article

Fulltext

XML

PubMed Links

Search on Google